Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vor Biopharma Inc. - Common Stock (NQ:VOR)

15.30 +0.60 (+4.08%)
Streaming Delayed Price Updated: 9:39 AM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vor Biopharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
News headline image
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
From Vor Biopharma
Via GlobeNewswire
Vor Bio Stock Jumped 19% Today And Retail Investors Are Eyeing A Breakout Rally: Here’s What’s Happening ↗
Via Stocktwits
News headline image
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Novartis Strengthens Kidney Disease Pipeline With Promising Data ↗
Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings planned for 2026. 
Via Benzinga
News headline image
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears ↗
Telitacicept showed strong efficacy and safety in a 48-week Phase 3 trial for Sjögren's disease, meeting all primary and secondary endpoints. 
Via Benzinga
News headline image
Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer
Dr. Khan brings decades of global medical affairs, commercial, and scientific leadership across multiple therapeutic areas including seven successful product launches 
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel
Experienced legal leader brings deep expertise in governance, strategic transactions, and risk management to support Vor Bio’s growth 
From Vor Biopharma
Via GlobeNewswire
News headline image
FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari ↗
FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing. 
Via Benzinga
News headline image
Vor Bio's Investigational Drug Scores Phase 3 Win In Autoimmune Kidney Disease Trial ↗
Vor Bio partner RemeGen reports Phase 3 success for telitacicept in IgA nephropathy, showing a 55% drop in proteinuria and plans for a China BLA filing. 
Via Benzinga
News headline image
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate ↗
Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's disease. 
Via Benzinga
News headline image
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunities 
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
From Vor Biopharma
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.